Enveric Biosciences, Inc. quarterly report, Q3 FY2009

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2009, for Spatializer Audio Laboratories, Inc. (Note: The input metadata listed "Enveric Biosciences," but the filing text explicitly identifies the registrant as Spatializer Audio Laboratories, Inc.). The company is a shell company with no active commercial operations, having ceased operations in 2006 and sold substantially all assets to DTS, Inc. in 2007. The entity currently exists solely to seek a merger or acquisition.

Key Financial Metrics

Metric Three Months Ended Sept 30, 2009 Nine Months Ended Sept 30, 2009 Balance Sheet (Sept 30, 2009)
Revenues $0 $0 N/A
Net Loss $(4,501) $(39,847) N/A
Operating Expenses $4,501 $34,794 N/A
Cash and Cash Equivalents N/A N/A $46,236
Total Assets N/A N/A $46,236
Total Liabilities N/A N/A $37,614
Shareholders' Equity N/A N/A $8,622
Working Capital N/A N/A $8,622

Debt and Liquidity: The company has no long-term debt. Current liabilities include $36,450 in accounts payable to related parties, representing a loan obtained on July 7, 2009, for working capital. Cash flow from operating activities for the nine-month period was a net use of $20,597.

Material Changes vs. Prior Period

  • Net Loss Reduction: Net loss for the three months ended September 30, 2009, decreased to $4,501 from $7,747 in the same period in 2008. For the nine-month period, the loss decreased to $39,847 from $108,621 in 2008.
  • Expense Reduction: General and administrative expenses declined significantly, driving the reduction in net loss.
  • Cash Position: Cash and cash equivalents decreased from $66,833 at December 31, 2008, to $46,236 at September 30, 2009, due to ongoing corporate maintenance costs.
  • Related Party Liability: A new liability of $36,450 was recorded for amounts borrowed from related parties, which was not present in the prior year-end balance sheet.

Outlook, Risks, and Management Commentary

  • Going Concern: The filing explicitly states that the company's circumstances raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
  • Strategy: Management plans to complete a merger, acquisition, or business combination. Until such an event occurs, the company does not expect to have significant operations.
  • Liquidity Risk: Management states they no longer believe they can maintain their liquidity position at a consistent level without additional financing or a transaction.
  • Tax Assets: The company has net operating loss carryforwards of approximately $26.2 million. However, due to a change in control, it is expected these will not be utilized to offset future taxable income.
  • Legal Proceedings: As of August 10, 2009, there were no legal proceedings expected to have a material adverse effect, though the company notes inherent litigation risks.

Investor Verification Checklist

  • Company Identity: Verify the registrant is Spatializer Audio Laboratories, Inc., not Enveric Biosciences (metadata discrepancy).
  • Shell Status: Confirm the company is a shell company with no revenue and minimal assets, relying entirely on a future merger for value.
  • Related Party Debt: Investigate the terms and repayment status of the $36,450 owed to related parties.
  • Liquidity Runway: Assess the sufficiency of the $46,236 cash balance against ongoing administrative burn rates.
  • Merger Progress: Determine if any specific merger or acquisition targets have been identified or if the company is actively soliciting partners.